1. Home
  2. CMPX vs MTLS Comparison

CMPX vs MTLS Comparison

Compare CMPX & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$2.15

Market Cap

408.8M

Sector

Health Care

ML Signal

HOLD

Logo Materialise NV

MTLS

Materialise NV

HOLD

Current Price

$6.85

Market Cap

387.8M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMPX
MTLS
Founded
2014
1990
Country
United States
Belgium
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
408.8M
387.8M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
CMPX
MTLS
Price
$2.15
$6.85
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
$14.57
N/A
AVG Volume (30 Days)
2.6M
53.9K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$6.38
Revenue Next Year
$934.41
$6.45
P/E Ratio
N/A
$61.39
Revenue Growth
N/A
N/A
52 Week Low
$1.61
$4.78
52 Week High
$6.88
$7.50

Technical Indicators

Market Signals
Indicator
CMPX
MTLS
Relative Strength Index (RSI) 45.27 55.25
Support Level $1.88 $6.36
Resistance Level $2.02 $6.89
Average True Range (ATR) 0.11 0.21
MACD -0.01 0.02
Stochastic Oscillator 37.33 87.50

Price Performance

Historical Comparison
CMPX
MTLS

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

About MTLS Materialise NV

Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.

Share on Social Networks: